|
業務類別
|
Biotechnology |
|
業務概覽
|
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function. |
| 公司地址
| 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037 |
| 電話號碼
| +1 858 795-4220 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inhibrx.com |
| 員工數量
| 110 |
| Mr. Mark Paul Lappe |
Chief Executive Officer and Chairman of the board |
美元 695.25K |
23/04/2026 |
| Mr. David J. Matly, M.B.A. |
President, Chief Commercial Officer and Chief Business Development Officer |
美元 589.17K |
23/04/2026 |
| Ms. Kelly D. Deck, C.P.A. |
Chief Financial Officer and Principal Accounting Officer |
美元 493.49K |
23/04/2026 |
|
|
| Ms. Kimberly J. Manhard |
Independent Director |
23/04/2026 |
| Dr. Jon Faiz Kayyem, PhD |
Independent Director |
23/04/2026 |
| Mr. Mark Paul Lappe |
Chief Executive Officer and Chairman of the board |
23/04/2026 |
| Dr. Kristiina Vuori, M.D.,PhD |
Independent Director |
23/04/2026 |
| Mr. Douglas G. Forsyth |
Independent Director |
23/04/2026 |
|
|
|
|
